Rosetta Genomics Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
86
- Stock Symbol
-
ROSGQ
- Investments
-
2
Rosetta Genomics General Information
Description
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Contact Information
Website
www.rosettagx.comCorporate Office
- 10 Plaut Street, Science Park
- POB 4059
- Rehovot 76706
- Israel
Corporate Office
- 10 Plaut Street, Science Park
- POB 4059
- Rehovot 76706
- Israel
Rosetta Genomics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 19.1K |
Rosetta Genomics Financials Summary
As of 30-Jun-2017, Rosetta Genomics has a trailing 12-month revenue of $5.83M.
|
In Thousands, USD |
TTM 30-Jun-2017 | FY 2016 31-Dec-2016 | FY 2015 31-Dec-2015 | FY 2014 31-Dec-2014 |
|---|---|---|---|---|
| EV | 3,714 | 3,935 | 11,873 | 16,326 |
| Revenue | 5,827 | 9,234 | 8,268 | 1,327 |
| EBITDA | (12,479) | (15,330) | (16,576) | (14,284) |
| Net Income | (13,390) | (16,233) | (17,345) | (14,526) |
| Total Assets | 6,207 | 11,961 | 22,423 | 17,278 |
| Total Debt | 2,449 | 3,795 | 0 | 0 |
Rosetta Genomics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Rosetta Genomics Comparisons
Industry
Financing
Details
Rosetta Genomics Competitors (12)
One of Rosetta Genomics’s 12 competitors is Asuragen, a Formerly VC-backed company based in Austin, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Asuragen | Formerly VC-backed | Austin, TX | ||||
| Guardant Health | Formerly VC-backed | Palo Alto, CA | ||||
| Foundation Medicine | Formerly VC-backed | Boston, MA | ||||
| Agendia | Venture Capital-Backed | Irvine, CA | ||||
| Hain Lifescience | Corporate Backed or Acquired | Nehren, Germany |
Rosetta Genomics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Rosetta Genomics Patents
Rosetta Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20180043036-A1 | Lipid assemblies and uses thereof and some ph and electrostatic modulating lipids to be used in said assemblies | Active | 04-Feb-2015 | ||
| WO-2016125163-A1 | Lipid assemblies and uses thereof and some ph and electrostatic modulating lipids to be used in said assemblies | Inactive | 04-Feb-2015 | ||
| CA-2945531-A1 | Mirna expression signature in the classification of thyroid tumors | Active | 13-May-2014 | ||
| CA-2945531-C | Mirna expression signature in the classification of thyroid tumors | Inactive | 13-May-2014 | ||
| EP-3143162-A1 | Mirna expression signature in the classification of thyroid tumors | Pending | 13-May-2014 | C12Q1/6886 |
Rosetta Genomics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Rosetta Genomics Acquisitions (2)
Rosetta Genomics’s most recent deal was a Merger/Acquisition with CynoGen for . The deal was made on 13-Apr-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CynoGen | 13-Apr-2015 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| Parkway Clinical Laboratories | 24-Jul-2008 | Merger/Acquisition | Laboratory Services (Healthcare) |
Rosetta Genomics Exits (2)
Rosetta Genomics’s most recent exit was on 13-Apr-2015 from CynoGen. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| CynoGen | 13-Apr-2015 | Completed |
|
||
| Parkway Clinical Laboratories | 24-Jul-2008 | Merger/Acquisition | Completed |
Rosetta Genomics FAQs
-
When was Rosetta Genomics founded?
Rosetta Genomics was founded in 2000.
-
Where is Rosetta Genomics headquartered?
Rosetta Genomics is headquartered in Rehovot, Israel.
-
What is the size of Rosetta Genomics?
Rosetta Genomics has 86 total employees.
-
What industry is Rosetta Genomics in?
Rosetta Genomics’s primary industry is Pharmaceuticals.
-
Is Rosetta Genomics a private or public company?
Rosetta Genomics is a Public company.
-
What is Rosetta Genomics’s stock symbol?
The ticker symbol for Rosetta Genomics is ROSGQ.
-
What is Rosetta Genomics’s current revenue?
The trailing twelve month revenue for Rosetta Genomics is $5.83M.
-
Who are Rosetta Genomics’s competitors?
Asuragen, Guardant Health, Foundation Medicine, Agendia, and Hain Lifescience are some of the 12 competitors of Rosetta Genomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
